# NCT03768570 (NCT03768570)

> Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03768570
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Cancer Trials Group
- Conditions: Bladder Cancer
- Interventions: Durvalumab
- Enrollment: 82
- Primary outcome: Disease-free survival

## Indexed commentary on NCT03768570 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03768570